Skip to main content

Caprion and ICOS Sign Protein Biomarker-Discovery Deal

NEW YORK, Jan. 18 (GenomeWeb News) - Caprion Pharmaceuticals said today that it will collaborate with ICOS to identify pharmacodynamic markers in plasma using its CellCarta proteomics platform.


Bothell, Wash.-based ICOS will use the research in its preclinical oncology programs, according to a statement.


The agreement builds upon a collaboration that Caprion and ICOS entered last March related to tumor antigen target discovery.


Financial details of the agreement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.